WANA (Oct 11) – Pars Isotope highlighted Iran’s scientific and technical capabilities on the international stage during the 39th European Association of Nuclear Medicine (EANM) Congress (EANM 2025).

 

As the country’s sole producer and supplier of diagnostic and therapeutic radiopharmaceuticals, Pars Isotope participated in the congress for the 14th consecutive year. Attending as an official corporate member of the European Association of Nuclear Medicine, the company aimed to showcase its scientific, technical, and industrial achievements to a global audience.

 

At the congress, Pars Isotope featured a 100-square-meter booth in the main exhibition area, presenting its latest innovations, products, and extensive capabilities in producing radiopharmaceuticals for nuclear medicine centers.

Pars Isotope’s Participation in the 39th European Congress of Nuclear Medicine

Pars Isotope’s Participation in the 39th European Congress of Nuclear Medicine. Social media/ WANA News Agency

Over the three-day event, more than 100 specialists, executives, and companies visited the booth, while over 30 specialized and managerial meetings were held to explore scientific and commercial collaboration opportunities.

 

Among the products showcased, the Pars-Gallogen generator, Renium skin cream, and Pars-Tecto PSM-A radiopharmaceutical kit attracted particular attention for their innovation and high demand. These products represent some of the newest advancements in global nuclear medicine, reflecting Iran’s advanced scientific and technical standing in the field.

 

Through its active participation in EANM 2025, Pars Isotope reaffirmed Iran’s scientific, technical, and production capabilities in advanced radiopharmaceuticals, cementing its role in the development of new technologies in nuclear medicine.

 

The 39th EANM Congress, aimed at advancing knowledge and facilitating scientific exchange in nuclear medicine, was held from October 4–8, 2025, in Barcelona, Spain.